Cost-effectiveness analysis of voglibose for prevention of type 2 diabetes mellitus in Japanese patients with impaired glucose tolerance

Journal of Diabetes Investigation

Volumn 1, Issue 6, 2010, Pages 252-258

  Ikeda, Shunya ^a   Kobayashi, Makoto ^b   Tajima, Naoko ^c  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Crecon Research and Consulting Inc   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cost effectiveness; Diabetes mellitus; Voglibose

Indexed keywords

VOGLIBOSE;

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DIABETES CONTROL; DIET THERAPY; EXERCISE; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; JAPANESE; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS;

EID: 79953734049     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00052.x     Document Type: Article

References (28)

1. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. The Year 2006 briefing of national medical costs. Available from: http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/06/index.html Accessed March 25, 2010 (in Japanese).
2. Oishi M. Health economics of diabetes. J Clin Exp Med 1999; 188: 538-540. (in Japanese).
3. Ministry of Health, Labour and Welfare. The National Health and Nutrition Survey in Japan, The year 2007. Available from: http://www.mhlw.go.jp/houdou/2008/12/h1225-5.html Accessed March 25, 2010 (in Japanese).
4. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167.
5. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata diabetes study. Diabetes Care 1999; 22: 920-924.
6. Hanefeld M, Temelkova-Kurktschiev T, Schaper F, et al. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 1999; 16: 212-218.
7. The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003; 26: 36-47.
8. The Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26: 2518-2523.
9. Herman WH, Hoerger TJ, Brandle M, et al.; Diabetes Prevention Program Research Group. The Cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-332.
10. Ramachandran A, Snehalatha C, Yamuna A, et al. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007; 30: 2548-2552.
11. Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004; 26: 304-321.
12. Caro JJ, Getsios D, Caro I, et al. Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med 2004; 21: 1229-1236.
13. Kawamori R, Tajima N, Iwamoto Y, et al.; the Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607-1614.
14. Ohizumi T. An epidemiologic investigation of the incidence of diabetes mellitus from impaired glucose tolerance in population based study. Jpn J Clin Med 2005; 63(Suppl 2): 73-77. (in Japanese).
15. Matsushima M, Tajima N, LaPorte RE, et al.; the Diabetes Epidemiology Research International (DERI) U.S.-Japan Mortality Study Group. Markedly increased renal disease mortality and incidence of renal replacement therapy among IDDM patients in Japan in contrast to Allegheny County, Pennsylvania, USA. Diabetologia 1995;38:236-243.
16. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. The year 2007 Abridged Life Tables. Available from: http://www.mhlw.go.jp/toukei/saikin/hw/life/life07/index.html Accessed March 25, 2010 (in Japanese).
17. Fuller JH, Shipley MJ, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980; 1: 1373-1376.
18. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
19. Nakagami T, DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385-394.
20. Maeda K. V. Measures to control end-stage renal failure and future prospects. 1. Long-term maintenance dialysis and its complications. J Jpn Soc Intern Med 1998; 87: 1311-1316. (in Japanese).
21. Hidaka H, Tsujinaka K, Yamasaki Y. Candidates and resources for primary prevention of type 2 diabete. Estimation from longitudinal data on medical checkups and later medical expenditure calculates using medical care health insurance claims. J Jpn Diab Soc 2005; 48: 841-847. (in Japanese).
22. Sugisaki H, Ota Y, Ohira S, et al. 11th Actual condition survey report of medical care expenditure for dialysis. J Jpn Soc Dial Ther 2008; 23: 49-94. (in Japanese).
23. Eguchi H, Igarashi K, Kimura M, et al. Incidence rate of diabe tes and risk factors in Funagata-machi, Yamagata-prefecture. J Jpn Diab Soc 1998; 41(Suppl): 487. (in Japanese).
24. Sasaki A, Shimizu T, Hasegawa K. Examination of risk factors involved in onset of diabetes - from the follow-up study by Person-year method. J Jpn Diab Soc 1994; 37(Suppl): 296. (in Japanese).
25. Ito C. Natural history of glucose-intolerance (borderline type) Jpn J Clin Med 1996; 54: 2624-2627. (in Japanese).
26. The Japan Diabetes Society. Evidence-Based Clinical Practice Guidelines for Diabetes, 2nd edn. Nankodo Co., Ltd., Tokyo. 2007. (in Japanese).
27. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med 2007; 24: 451-463.
28. Sone H, Mizuno S, Fujii H, et al. On behalf of the Japan Diabetes Complications Study (JDCS) Group. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005;28: 1463-1471.